| Literature DB >> 23320821 |
Yifan Huang1, Xiaoxia Li, Maoqing Wang, Hua Ning, Lima A, Ying Li, Changhao Sun.
Abstract
BACKGROUND: Lipoprotein lipase (LPL) and serum 25-hydroxyvitamin D [25(OH)D] play important roles in the regulation of lipid metabolism. Although dyslipidemia is associated with insulin resistance (IR) and type 2 diabetes (T2D), there are limited data available regarding the relationship of LPL and 25(OH)D to IR and T2D at a population level. The objective of the present study is to investigate the associations of LPL and 25(OH)D with IR and T2D in a Chinese population.Entities:
Mesh:
Substances:
Year: 2013 PMID: 23320821 PMCID: PMC3570389 DOI: 10.1186/1475-2840-12-17
Source DB: PubMed Journal: Cardiovasc Diabetol ISSN: 1475-2840 Impact factor: 9.951
Demographic and clinical characteristics for males and females
| N | 1326 | 1382 | |
| | | | |
| Age, y | 47.6 ± 11.3 | 49.4 ± 13.1 | <0.001 |
| BMI, kg/m2 | 25.7 ± 3.8 | 25.2 ± 3.3 | 0.002 |
| Physical activity level | 1.45 ± 0.40 | 1.49 ± 0.42 | 0.011 |
| Insulin Resistance, n (%) | 288 (21.7) | 240 (17.4) | 0.004 |
| Type 2 diabetes, n (%) | 243 (18.3) | 189 (13.7) | <0.001 |
| Obesity, n (%) | 273 (20.6) | 283 (20.5) | 0.943 |
| Alcohol use, n (%) | 797 (60.1) | 170 (12.3) | <0.001 |
| Smoking, n (%) | | | <0.001 |
| Never | 541 (40.8) | 1273 (92.1) | |
| Past | 164 (12.4) | 23 (1.7) | |
| Current | 621 (46.8) | 86 (6.2) | |
| | | | |
| 25(OH)D, ng/ml | 25.7 ± 6.7 | 25.1 ± 6.4 | 0.017 |
| FG, mmol/L | 5.1 (3.6-9.2) | 4.9 (3.4-10.3) | 0.054 |
| PG, mmol/L | 7.9 (3.8-14.5) | 7.6 (3.5-13.6) | 0.011 |
| HbAlc, % | 4.3 (3.4-11.7) | 3.9 (3.3-11.5) | 0.002 |
| Insulin, mU/L | 6.1 (1.5-17.5) | 6.0 (1.4-16.8) | 0.051 |
| HOMA-IR | 1.4 (0.3-6.2) | 1.3 (0.3-6.0) | 0.011 |
| TC, mmol/L | 4.8 ± 1.1 | 4.9 ± 1.2 | 0.024 |
| TG, mmol/L | 1.7 (0.5-6.1) | 1.5 (0.4-5.9) | <0.001 |
| HDL-C, mmol/L | 1.5 (0.8-2.3) | 1.5 (0.7-2.4) | 0.286 |
| LDL-C, mmol/L | 3.0 (0.6-5.2) | 2.9 (0.5-5.4) | 0.118 |
| apoA, mmol/L | 1.8 ± 0.4 | 2.0 ± 0.4 | <0.001 |
| apoB, mmol/L | 0.8 ± 0.2 | 0.7 ± 0.3 | <0.001 |
| FFAs, μmol/L | 723.8 ± 293.7 | 729.4 ± 265.4 | 0.602 |
| LPL, U/L | 653.1 ± 187.8 | 664.3 ± 193.5 | 0.127 |
Data are presented as n(%), means ± SD or median (range). χ2 test or ANOVA were adopted to compare differences between males and females.
Abbreviations: FFAs, free fatty acids; FG, fasting serum glucose; HOMA-IR, Homeostasis model of assessment - insulin resistance; LPL, lipoprotein lipase; PG, 2 h post-load glucose; TC, total cholesterol; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; TG, triglyceride.
Characteristics of study variables by lipoprotein lipase quartile groups
| | |||||
| 677 | 677 | 677 | 677 | | |
| | | | | ||
| Age, y | 49.2 ± 12.6 | 47.9 ± 12.3 | 48.3 ± 10.1 | 48.6 ± 11.4 | 0.213 |
| BMI, kg/m2 | 25.6 ± 3.8 | 25.2 ± 3.5 | 25.3 ± 3.6 | 25.1 ± 3.1 | 0.053 |
| Physical activity level | 1.49 ± 0.39 | 1.46 ± 0.47 | 1.50 ± 0.44 | 1.47 ± 0.38 | 0.283 |
| Obesity, n (%) | 158 (23.3) | 142 (21.0) | 135 (19.9) | 121 (17.9) | 0.093 |
| | | | | | |
| 25(OH)D, ng/ml | 23.1 ± 6.7 | 24.6 ± 6.3 | 26.4 ± 6.2 | 27.8 ± 7.1 | <0.001 |
| FG, mmol/L | 5.2 (3.5-11.5) | 5.0 (3.3-10.8) | 4.9 (2.8-10.7) | 4.9 (3.0-11.2) | 0.021 |
| PG, mmol/L | 8.0 (3.6-13.3) | 7.7 (3.5-12.7) | 7.6 (3.1-12.1) | 7.4 (3.0-12.4) | 0.008 |
| HbAlc, % | 4.3 (3.2-11.9) | 4.2 (3.3-12.5) | 4.0 (3.2-11.4) | 3.9 (3.2-11.7) | <0.001 |
| Insulin, mU/L | 6.0 (1.4-17.6) | 5.8 (1.5-17.9) | 5.9 (1.6-17.7) | 5.8 (1.4-18.1) | 0.149 |
| HOMA-IR | 1.5 (0.3-6.6) | 1.4 (0.4-6.4) | 1.4 (0.2-6.0) | 1.3 (0.3-5.9) | <0.001 |
| TC, mmol/L | 4.8 ± 1.2 | 4.7 ± 1.1 | 4.9 ± 1.3 | 4.8 ± 1.2 | 0.201 |
| TG, mmol/L | 1.9 (0.6-6.2) | 1.8 (0.5-6.0) | 1.5 (0.7-5.6) | 1.5 (0.6-5.9) | <0.001 |
| HDL-C, mmol/L | 1.4 (0.7-2.1) | 1.4 (0.6-2.4) | 1.5 (0.7-2.3) | 1.5 (0.8-2.5) | 0.032 |
| LDL-C, mmol/L | 3.0 (0.7-5.3) | 3.0 (0.6-5.1) | 2.9 (0.5-4.9) | 2.9 (0.5-5.2) | 0.068 |
| apoA, mmol/L | 1.9 ± 0.4 | 1.9 ± 0.5 | 2.0 ± 0.4 | 2.1 ± 0.5 | <0.001 |
| apoB, mmol/L | 0.8 ± 0.2 | 0.8 ± 0.3 | 0.8 ± 0.2 | 0.8 ± 0.3 | 0.470 |
| FFAs, μmol/L | 776.4 ± 293.2 | 741.3 ± 295.4 | 713.2 ± 289.7 | 685.4 ± 278.5 | <0.001 |
Data are presented as n(%), means ± SD or median (range). χ2 test or ANOVA were adopted to compare the difference among LPL quartile groups.
Abbreviations: FFAs, free fatty acids; FG, fasting serum glucose; LPL, lipoprotein lipase; PAL, Physical activity level; PG: 2 h post-load glucose; TC, total cholesterol; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; TG, triglyceride.
Means or medians by serum 25 (OH)D status and regression coefficients of serum 25(OH)D on metabolic variables
| 422 | 1602 | 684 | | | | | |
| 5.3 (3.6-11.5)* | 5.0 (3.1-9.3) | 4.9 (2.7-8.8) | −0.086 | 0.011 | −0.055 | 0.034 | |
| 8.5 (3.7-13.9)* | 7.8 (3.5-12.4) | 7.7 (3.2-12.1) | −0.091 | 0.002 | −0.058 | 0.027 | |
| 4.4 (3.3-11.5)** | 4.2 (3.2-11.8)** | 4.0 (3.3-11.6) | −0.120 | <0.001 | −0.082 | 0.012 | |
| 5.9 (1.5-16.9) | 6.1 (1.4-17.8) | 6.0 (1.6-18.1) | −0.045 | 0.051 | −0.042 | 0.058 | |
| 1.5 (0.3-6.5)** | 1.4 (0.3-6.1)* | 1.3 (0.3-5.8) | −0.127 | <0.001 | −0.048 | 0.047 | |
| 5.0 ± 1.2 | 4.8 ± 1.3 | 4.8 ± 1.2 | −0.014 | 0.532 | −0.015 | 0.525 | |
| 1.8 (0.8-6.3)* | 1.6 (0.5-6.1) | 1.5 (0.6-5.8) | −0.093 | 0.001 | −0.043 | 0.056 | |
| 1.4 (0.7-2.2)* | 1.5 (0.8-2.4) | 1.5 (0.8-2.3) | 0.117 | <0.001 | 0.084 | 0.011 | |
| 3.0 (0.8-5.3) | 2.9 (0.7-5.2) | 2.9 (0.5-5.5) | −0.021 | 0.431 | −0.018 | 0.513 | |
| 1.9 ± 0.4* | 2.0 ± 0.4 | 2.0 ± 0.3 | 0.089 | 0.005 | 0.052 | 0.028 | |
| 0.8 ± 0.2 | 0.8 ± 0.3 | 0.8 ± 0.2 | 0.024 | 0.353 | 0.022 | 0.358 | |
| 778.6 ± 284.8** | 734.5 ± 306.4* | 672.8 ± 297.5 | −0.145 | <0.001 | −0.077 | 0.021 | |
| 615.3 ± 192.4** | 658.8 ± 196.6* | 691.2 ± 194.1 | 0.168 | <0.001 | NA | NA | |
Means ± SD or medians ( range). * P < 0.05, ** P < 0.01, compared with vitamin D sufficiency group by ANCOVA, adjusted for age, sex, BMI, physical activity level, smoking and alcohol consumption.
Multivariable linear regression analyses model 1, with 25(OH)D concentration as the independent variable, adjusted for age, sex, BMI, physical activity level, smoking and alcohol consumption.
Multivariable linear regression analyses model 2, with 25(OH)D concentration as the independent variable adjusted for covariates in model 1 + LPL.
Abbreviations: FFAs, free fatty acids; FG, fasting serum glucose; LPL, lipoprotein lipase; PAL, Physical activity level; PG: 2 h post-load glucose; TC, total cholesterol; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; TG, triglyceride; β, regression coefficients.
Associations of serum 25(OH)D and LPL with IR and T2D
| | ||||||||||
| | ||||||||||
| Cases/Non-cases | 101/321 | 324/1278 | 103/581 | 159/518 | 143/534 | 128/549 | 98/579 | |||
| Model 1 | 1.91 (1.23-2.76) | 1.42 (1.04-1.87) | 1.00 (reference) | 1.85 (1.22-2.68) | 1.51 (1.03-2.25) | 1.32 (0.91-1.93) | 1.00 (reference) | |||
| Model 2 | 1.35 (1.12-2.45) | 1.13 (1.02-1.82) | 1.00 (reference) | NA | NA | NA | NA | |||
| Cases/Non-cases | 87/335 | 269/1333 | 76/608 | 124/553 | 113/564 | 101/576 | 94/583 | |||
| Model 1 | 2.06 (1.37-3.24) | 1.57 (1.12-2.29) | 1.00 (reference) | 1.65 (1.14-2.38) | 1.41 (1.07-2.25) | 1.29 (0.84-1.96) | 1.00 (reference) | |||
| Model 2 | 1.42 (1.09-2.68) | 1.10 (1.03-1.93) | 1.00 (reference) | NA | NA | NA | NA | |||
Model 1, adjusted for age, sex, BMI, PAL, smoking and alcohol consumption.
Model 2, adjusted for covariates in model 1 + LPL.
25(OH)D, 25-hydroxyvitamin D; IR, insulin resistance; T2D, type 2 diabetes; LPL, lipoprotein lipase; PAL, physical activity level.
Figure 1Putative scheme of effect of vitamin D on insulin resistance and type 2 diabetes. Vitamin D deficiency influences the pathogenesis of insulin resistance and type 2 diabetes by direct effect such as decreased binding to vitamin D receptor (VDR), and indirect effect such as aberrant calcium flux. Reductive serum 25(OH)D concentration was accompanied with decreased LPL and increased TG in our study, which might be associated with insulin resistance and type 2 diabetes.